Dr. Robert Franklin, MD
Claim this profileUniversity of Cincinnati Cancer Center-UC Medical Center
Studies Renal Cell Carcinoma
Studies Kidney Cancer
4 reported clinical trials
15 drugs studied
Affiliated Hospitals
Clinical Trials Robert Franklin, MD is currently running
Radium-223 + Docetaxel
for Prostate Cancer
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Recruiting2 awards Phase 323 criteria
Immunotherapy With or Without Surgery
for Kidney Cancer
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.
Recruiting2 awards Phase 316 criteria
More about Robert Franklin, MD
Clinical Trial Related7 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Robert Franklin, MD has experience with
- Ipilimumab
- Nivolumab
- Cabozantinib
- Avelumab
- Axitinib
- Cytoreductive Nephrectomy
Breakdown of trials Robert Franklin, MD has run
Renal Cell Carcinoma
Kidney Cancer
Rhabdoid Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert Franklin, MD specialize in?
Robert Franklin, MD focuses on Renal Cell Carcinoma and Kidney Cancer. In particular, much of their work with Renal Cell Carcinoma has involved Stage IV patients, or patients who are undergoing treatment.
Is Robert Franklin, MD currently recruiting for clinical trials?
Yes, Robert Franklin, MD is currently recruiting for 2 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Robert Franklin, MD has studied deeply?
Yes, Robert Franklin, MD has studied treatments such as Ipilimumab, Nivolumab, Cabozantinib.
What is the best way to schedule an appointment with Robert Franklin, MD?
Apply for one of the trials that Robert Franklin, MD is conducting.
What is the office address of Robert Franklin, MD?
The office of Robert Franklin, MD is located at: University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio 45219 United States. This is the address for their practice at the University of Cincinnati Cancer Center-UC Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.